Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$1.38.

  • Cartesian Therapeutics' EPS (Basic) fell 2212.39% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.42, marking a year-over-year increase of 9730.09%. This contributed to the annual value of -$4.48 for FY2024, which is 9099.4% up from last year.
  • Cartesian Therapeutics' EPS (Basic) amounted to -$1.38 in Q3 2025, which was down 2212.39% from $0.51 recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EPS (Basic) ranged from a high of $0.58 in Q2 2024 and a low of -$41.56 during Q4 2023
  • For the 5-year period, Cartesian Therapeutics' EPS (Basic) averaged around -$3.35, with its median value being -$0.22 (2021).
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 20454.55% in 2022, then tumbled by 10219003.13% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' EPS (Basic) (Quarter) stood at $0.12 in 2021, then crashed by 66.08% to $0.04 in 2022, then plummeted by 102190.03% to -$41.56 in 2023, then skyrocketed by 96.62% to -$1.41 in 2024, then grew by 1.79% to -$1.38 in 2025.
  • Its EPS (Basic) was -$1.38 in Q3 2025, compared to $0.51 in Q2 2025 and -$0.68 in Q1 2025.